Mereo BioPharma Group Plc(NASDAQ) MREO

Mereo develops medicines for rare diseases and cancer. Its treatments aim to help people with genetic bone disorders and lung conditions. The company works with partners to bring new therapies to patients who have few options.

What’s in the Medicine Cabinet?

• Setrusumab: Antibody treatment for brittle bone disease (osteogenesis imperfecta); targets children and adults with this rare genetic disorder. 0% of revenue in 2025.
• Alvelestat: Oral drug for a rare lung disease (alpha-1 antitrypsin deficiency); for patients with inherited lung problems. 0% of revenue in 2025.
• Vantictumab: Antibody for a rare bone disorder (autosomal dominant osteopetrosis type 2); licensed to partners, with Mereo keeping some regional rights. 0% of revenue in 2025.
• Leflutrozole: Oral therapy for hormone-related infertility in men; licensed to ReproNovo, with milestone payments. 100% of 2025 revenue from milestone/license payments.
• Navicixizumab and Etigilimab: Cancer therapies for ovarian and solid tumors; available for partnering, not generating revenue in 2025.

Growth Spurts and Strategic Moves

• Partnered with Ultragenyx in 2020 for setrusumab, keeping Europe/UK rights.
• Out-licensed vantictumab to āshibio in August 2025 for global development.
• Licensed leflutrozole to ReproNovo in December 2023, earning milestone payments.
• Licensed navicixizumab to Feng Biosciences in January 2020 for global rights.
• Raised $50 million in June 2024 and $12 million in July 2023 to fund operations.

Why Mereo Is a Bit Different

Mereo focuses on rare diseases and cancer, acquiring late-stage drug candidates from larger companies. It partners with other firms to share costs and speed up development. The company keeps rights in Europe and the UK, while out-licensing elsewhere to reduce risk.

Five Things You Need to Know

• Revenue was $0 in QQ3 2025, down 100% from QQ3 2023.
• Net loss was $41.9 million in 2025, a 3.2% improvement from 2024.
• Cash and equivalents were $41 million at December 31, 2025, down 41.3% from 2024.
• R&D expenses were $17.8 million in 2025, down 14.9% from 2024.
• Operating cash outflow was $31 million in 2025, a 5.5% improvement from 2024.

Bottom Line

Mereo has shifted from direct drug development to a partnership-driven model. The company relies on milestone payments and collaborations to advance rare disease and cancer therapies.